Price T Rowe Associates Inc Summit Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $935 Billion
- Q3 2025
A detailed history of Price T Rowe Associates Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,538,823 shares of SMMT stock, worth $82.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,538,823
Previous 3,905,148
16.23%
Holding current value
$82.8 Million
Previous $83.1 Million
12.84%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding SMMT
# of Institutions
268Shares Held
94.6MCall Options Held
4.72MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.13MShares$57.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...